Eli Lilly: Far From Dead In Alzheimer’s, But Needs Help From Other Areas


  • The recent FDA complete response letter to Eli Lilly and Company about donanemab was inevitable.
  • Approval of donanemab remains uncertain.
  • There are several regulatory events for Eli Lilly and Company in 2023.
Eli Lilly and Company Research Laboratories. Lilly makes Medicines and Pharmaceuticals.


On January 19, Eli Lilly and Company (NYSE:LLY), one of the largest ($329 billion market cap) global health care companies, received the U.S. Food and Drug Administration’s (FDA) complete response letter (“CRL”) to the biologics license application (“BLA”) for donanemab under the accelerated approval pathway for the treatment of

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *